Navigation Links
Exemestane plus everolimus increased progression-free survival
Date:12/7/2011

SAN ANTONIO Everolimus in combination with exemestane has shown promise for the treatment of breast cancer.

"For postmenopausal patients with hormone receptor (HR)-positive metastatic breast cancer, the addition of everolimus to exemestane markedly improves the duration of disease control," said Gabriel N. Hortobagyi, M.D., FACP, professor of medicine, chair of the department of breast medical oncology and director of the Multidisciplinary Breast Cancer Research Program at the University of Texas MD Anderson Cancer Center in Houston.

Hortobagyi presented findings from Breast Cancer Trials of Oral Everolimus (BOLERO-2), a phase 3 clinical trial, at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011.

BOLERO-2 researchers enrolled 724 postmenopausal patients with HR-positive metastatic breast cancer and evidence of progressive disease while receiving anastrozole or letrozole. They randomly assigned patients to treatment with exemestane plus everolimus or with exemestane plus placebo.

Results revealed a median progression-free interval of 3.2 months for 239 patients treated with exemestane plus placebo. Among the 485 patients treated with exemestane plus everolimus, researchers found a median progression-free interval of 7.4 months, "a highly significant difference," Hortobagyi said.

Clinical benefit rates, which include complete response, partial response, or stable disease exceeding six months, were 25.5 percent among patients treated with exemestane and placebo and 50.5 percent among those treated with exemestane and everolimus.

"The original hypothesis predicted this increased benefit from the combination, based on compelling preclinical experiments and preliminary results from earlier, smaller clinical trials. These results establish a new standard of care for this group of patients," Hortobagyi said.

He continued, "These results highlight the progress being made in understanding the evolving mechanisms of resistance to standard therapies."

Researchers were not yet able to measure survival analysis in BOLERO-2. However, treatment was well tolerated, with oral mucositis, fatigue, pneumonitis and hyperglycemia being the most common side effects.


'/>"/>
Contact: Jeremy Moore
jeremy.moore@aacr.org
210-582-7021
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Study finds everolimus-eluting stent safer, more effective than paclitaxel-eluting stent
2. Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors
3. Studies show everolimus-eluting stent implantation reduces restenosis and repeat revasculariztion
4. Everolimus improves progression-free survival for patients with rare pancreatic cancer
5. Clinical outcomes in PCI patients given sirolimus-eluting and everolimus-eluting stents
6. An important reduction in risk of stent thrombosis with everolimus-eluting stent
7. Everolimus prolongs progression-free survival for patients with neuroendocrine tumors
8. Migraine Linked to Increased Heart Attack Risk
9. Attorney Joe Belluck Hails Department Of Defense For Increased Funding Of Mesothelioma Research
10. Increased HAART coverage associated with 50 percent drop
11. RetireSafe Survey Says Seniors Are Struggling With Increased Costs Without an Increased Social Security Cost of Living Adjustment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology: